How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Thomas J Catalano is a CFP and Registered Investment Adviser with the state of South Carolina, where he launched his own financial advisory firm in 2018. Thomas' experience gives him expertise in a ...

View the basic RXRX option chain and compare options of Recursion Pharmaceuticals, Inc. on Yahoo Finance.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Recursion Pharmaceuticals insiders reported 6 transactions totaling $589,430.56. Activity included 2 tax payments, 2 sales, and 2 stock awards between July and August 2026. View more Major Holders ...

The 247Sports Composite is a proprietary algorithm that compiles rankings and ratings listed in the public domain by the major media recruiting services, creating the ...